Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211555 · ClinicalTrials.gov registry record · NA
The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy
A NA study, sponsored by AdventHealth.
- Not yet
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT07211555: Clinical Trial NA study, sponsored by AdventHealth.
NCT07211555 is a NA study that has not yet begun recruiting, run by AdventHealth. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07211555, a NA study, has not yet begun recruiting, sponsored by AdventHealth.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is being done to evaluate a new robotic system that helps urologists more precisely reach the kidney during surgery to remove large kidney stones. The procedure, called percutaneous nephrolithotomy (PCNL), is typically used for people who have large or difficult-to-remove kidney stones. Traditionally, many urologists rely on radiologists to place a tube into the kidney before surgery. This can cause delays, require multiple procedures, and increase costs. The robotic system being studied - called LARC - is designed to help the urologist safely and accurately guide a needle directly into the kidney during the surgery, without needing a separate procedure beforehand. The robot uses live X-ray images to help align the instruments. Although parts of the robot have been approved by the U.S. FDA, the version used in this study is still investigational and not yet approved for this specific purpose. The study will take place at AdventHealth Celebration and include up to 45 adult patients who are scheduled for PCNL surgery. Participants will be followed for up to 1 month after surgery, and doctors will look at outcomes such as the success of the procedure, the number of kidney stones removed, complications, time in surgery, and radiation exposure. This research may help make kidney stone surgery safer, faster, and more effective in the future.
Primary Outcome
Proportion of participants with no residual kidney stones larger than 4 mm, as determined by imaging (non-contrast CT, KUB X-ray, or renal ultrasound).
Interventions
- DEVICE LARC Robotic System (Micromate™ Version 3.0)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2026-01-01 |
| Phase | NA |
What is known before NCT07211555 opens enrollment
NCT07211555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which LARC Robotic System (Micromate™ Version 3.0) is the first listed.
NCT07211555 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07211555 about?
NCT07211555 is a clinical study titled "The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy". This study is being done to evaluate a new robotic system that helps urologists more precisely reach the kidney during surgery to remove large kidney stones. The procedure, called percutaneous nephrolithotomy (PCNL), is typically used for people who have large or difficult-to-remove kidney stones. ...
What is the current status of trial NCT07211555?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-11-01. Estimated completion is 2026-01-01.
What interventions are being tested in trial NCT07211555?
The interventions under investigation include: LARC Robotic System (Micromate™ Version 3.0) (DEVICE).
Who is sponsoring clinical trial NCT07211555?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07211555's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI